Quantori Expands Executive Team, Appoints Sean Murphy as Vice President, Client Services
20.7.2021 13:00:00 EEST | Business Wire | Press release
Quantori, a leading data science and digital transformation services company for the life sciences and healthcare sectors, today announced the appointment of Sean Murphy as Vice President of Client Services, effective immediately. Sean will oversee Quantori’s global network of IT professionals providing world-class software engineering and data analytics services to top biopharma and healthcare companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005589/en/
Sean Murphy, Vice President, Client Services, Quantori (Photo: Business Wire)
“Sean has a strong track record of leading cross-functional teams to deliver innovative digital IT solutions that support a seamless digital transformation experience,” said Richard Golob, CEO of Quantori. “As we enter our next phase of growth, we are thrilled to welcome Sean aboard to ensure delivery of cost-effective, high-quality data science and software engineering services.”
Sean has held various leadership positions at AstraZeneca and Thermo Fisher Scientific, where he focused primarily on R&D IT and Cloud and Digital Transformations. At AstraZeneca, Sean designed, developed, and led the Application Lifecycle Services organization, a world-class software engineering team that delivers quality products and services throughout AstraZeneca. He also was instrumental in establishing captive offshore development centers for AstraZeneca.
Most recently, Sean served as Vice President at General Electric, where he was the Technology Leader for the business and digital transformation of corporate systems. He focused predominately on the implementation of the enterprise SaaS solution Workday across all General Electric businesses.
Sean received his B.S. degree in Business Administration from the University of New Hampshire and his M.Sc. degree in Management with a specialization in Biopharmaceutical Leadership from Emmanuel College. He currently serves as a board member of the United Nations Association of Greater Boston and has served as a board member of the Society for Information Management of Boston and Newton Girls Soccer.
“I’m excited to join the highly impressive Quantori leadership team to help deliver nextgen data science and software solutions that provide immediate value for our clients,” according to Sean. “While at AstraZeneca, I had the pleasure of working with some of the professionals who are now Quantori’s leaders. They were the only service providers who truly understood the drug development process and the scientific problems we were trying to solve. I was so impressed with their performance and ability to deliver that I wanted to join the team!”
Quantori’s executive leadership boasts a rich history in the life sciences and healthcare IT industry. CEO Richard Golob, Chief Scientific Officer Yuriy Gankin, Ph.D., and Chief Technology Officer Vitaliy Aronov have successfully joined forces for more than two decades to deliver award-winning software engineering and data analytics services to top pharmaceutical companies and research organizations around the globe. They previously cofounded GGA Software Services, which was acquired by EPAM Systems in 2014. Golob built EPAM’s Life Sciences Business Unit into the fastest growing unit at the company.
“What we’ve experienced over the past year is that our clients require a versatile digital IT services provider that understands their needs for scalability and flexibility and has deep domain and data science knowledge, and Quantori checks all these boxes,” said Yuriy Gankin, Chief Scientific Officer at Quantori. “Sean’s background in helping organizations navigate the digital revolution will be invaluable in helping us fulfill our mission to empower our clients to achieve their strategic business goals.”
Quantori’s global headquarters are located in Cambridge, Massachusetts, with additional offices in London, U.K., St. Petersburg, Russia, and Tbilisi, Georgia. The company serves leading research institutions and biopharma organizations, including Bruker, The Jackson Laboratory, Perkin Elmer, and Takeda. Quantori’s team is currently more than 400 professionals, and the company is actively seeking qualified experts globally to keep pace with its rapid growth. For more information, please visit www.quantori.com or email info@quantori.com.
“The robust software engineering, scientific informatics and data science capabilities that Quantori offers have enabled us to achieve our IT strategy by harnessing the power of innovative digital technologies,” said Scott Thomas, Vice President of Information Technology for the LGC Genomics Division. “The COVID-19 pandemic has significantly increased demand for genomic analysis, and Quantori’s digital solutions have helped optimize our operations to meet the demand for these mission-critical applications.”
About Quantori
Quantori is transforming life sciences and healthcare with the power of digital IT. The company develops bespoke IT and data science solutions for accelerating research and drug discovery and improving healthcare delivery. Quantori combines data engineering and advanced analytics with scientific knowledge management and best-in-class software engineering to help life science and healthcare companies successfully achieve their digital transformations with greater speed and agility. Learn more at www.quantori.com and connect on social media @Twitter, @LinkedIn , and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005589/en/
Contact information
Heidi Creighton
heidi.creighton@quantori.com
Mobile/Text: 978-302-1198
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Partnership Between Record Asset Management and Admicasa2.7.2026 20:00:00 EEST | Press release
RAM Swiss Holding AG is a subsidiary of LSE-listed Record Financial Group (Record) and part of the Record Asset Management (RAM) group of companies. The partnership is a milestone in the growth of Admicasa and marks an important step in the continued expansion of Record’s private markets platform. Subject to regulatory approval, the agreement, signed on 1st July 2026, provides RAM Swiss Holding AG with a 50% participation in the Admicasa Fondsleitung AG, part of Admicasa, and establishes a long-term partnership to develop investment opportunities in the Swiss and Global real estate market with a plan to expand into other asset classes in the medium term. RAM is the European asset management arm of Record, the LSE-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom it has built long-standing relationships th
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 17:47:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quantum computing company listed on a major U.S. stock exchange. Due to the proceeds of the transaction, IQM maintains a strong pro forma cash position of EUR 337 million. IQM enters the public markets with strong commercial momentum and a rapidly expanding globa
GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio2.7.2026 17:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced today the launch of its new GD24CL series I²C EEPROM. The series delivers outstanding performance, comprehensive security protection mechanisms, and excellent reliability that addresses the stringent requirements for stable and long-term storage of critical configuration data. These offered features will benefit applications in industrial, energy, Internet-of-Things (IoT), data centers, and networking. As GigaDevice’s first EEPROM product series, the launch further enhances the company’s non-volatile memory portfolio and provides customers with more dynamic storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702394554/en/ GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio. The GD24CL series is designed with high
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur ® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 14:00:00 EEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom